ROCKVILLE, Md., April 20, 2016 /PRNewswire/ -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that Dr. Thomas F. Miller, President and Chief Executive Officer, will present at the World Orphan Drug Congress USA 2016, to be held April 21-22 at the Washington Hilton in Washington, D.C. Dr. Miller's presentation, entitled, "Recombinant human secretoglobins: therapeutic applications in orphan respiratory disease," is scheduled for Thursday, April 21, 2016 at 11:40am ET.
About Therabron Therapeutics, Inc.
At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins, which includes the CC10 protein — a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class biologic therapeutics. For additional information, please visit www.therabron.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therabron-therapeutics-to-present-at-world-orphan-drug-congress-usa-2016-300254458.html
SOURCE Therabron Therapeutics, Inc.